Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proceedings of the 2007 Annual Meeting of the American Association for Cancer Research. 2007; abstract 3521.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.